ArticleRegenerative therapy2026
The favorable role of recombinant collagen peptide in periosteal cell-derived osteoregeneration.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human periosteal cells (hPCs) possess high osteogenic potential and are considered promising candidates for regenerative therapy. Recombinant human collagen peptide (RCP), a xeno-free biomaterial enriched with arginine-glycine-aspartic acid (RGD) sequences, provides a stable and biocompatible scaffold that may enhance cellular functions. Objectives: This study aimed to evaluate the biocompatibility of RCP with hPCs and its effects on osteogenic functions Materials and methods: Cell viability was assessed by MTT assay at various RCP concentrations. Cell adhesion and migration were examined using fluorescence-based adhesion and Oris™ migration assays. Gene expression profiles were analyzed by RNA-sequencing and quantitative PCR. Alkaline phosphatase assay (ALP) and Alizarin Red staining (ARS) were performed to evaluate osteogenic differentiation. For Results: RCP exhibited no cytotoxic effects and enhanced the adhesion and migration of hPCs. RNA-seq and qPCR analyses revealed upregulation of extracellular matrix- and osteogenesis-related genes, including COL1A1, SERPINH1, ALP, RUNX2, and OCN. Moreover, RCP enhanced osteogenic differentiation, as demonstrated by increased ALP activity and greater calcium deposition in ARS. Conclusion: RCP supports the osteogenic potential of hPCs by promoting adhesion, migration, and osteogenesis-related gene expression, and enhancing osteogenic activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.